Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

@article{Westin2014StatusOP,
  title={Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.},
  author={Jason R Westin},
  journal={Clinical lymphoma, myeloma & leukemia},
  year={2014},
  volume={14 5},
  pages={
          335-42
        }
}
The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma

  • Journal of experimental & clinical cancer research : CR
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 108 REFERENCES

NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

ON Ozes, LD Mayo, +3 authors DB. Donner
  • Nature
  • 1999
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

ON Ozes, LD Mayo, +3 authors DB. Donner
  • Nature
  • 1999
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Final report of a phase I study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent nonHodgkin lymphoma (abstract)

B Kahl, R Furman, I Flinn
  • Hematol Oncol
  • 2013
VIEW 1 EXCERPT

Final report of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with relapsed or refractory mantle cell lymphoma (abstract)

J Leonard, B Kahl, R Furman
  • Hematol Oncol
  • 2013

Final report of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with relapsed or refractory mantle cell lymphoma (abstract)

J Leonard, B Kahl, R Furman
  • Hematol Oncol
  • 2013